Hospital Israelita Albert Einstein, Av. Albert Einstein, 627, Sala 303, Bloco A1, São Paulo, SP, Brazil.
Institut Mutualiste Montsouris, Paris, France.
BMC Urol. 2020 Oct 20;20(1):163. doi: 10.1186/s12894-020-00734-y.
The Expanded Prostate Index Composite for Clinical Practice (EPIC-CP) is a short version of the original EPIC, developed to facilitate the instrument's use in routine care. This study aimed to validate the EPIC-CP Portuguese version, and evaluate its role in presenting early functional outcomes of surgically treated prostate cancer patients at a Latin American referral center.
The EPIC-CP was self-administered prospectively and individually by all localized prostate cancer patients, before and after robotic-assisted radical prostatectomy, from March 2017 to June 2018 at a single institution. For validation, we used the Cronbach's alpha coefficient to evaluate internal consistency. The EPIC-CP domains were compared before surgery, and 6 months and 12 months after surgery. Statistical analyses were performed using the student's t test, and Wilcoxon and Friedman tests, with p values < 0.05 considered significant.
One hundred and fifty two patients answered the EPIC-CP. The patients had a median age of 62.7 (± 8.5) years and prostate specific antigen level of 6.3 (± 4.6) ng/ml. The Cronbach's alpha varied from 0.75 to 0.77 for all domains with good internal consistency, except for the "vitality/hormonal" domain, which had a score of 0.35. The domain evolution for the preoperative and 6-month postoperative groups revealed that the domains related to urinary continence and bowel worsened, and were increased during the first 6 months; however, this variation had no obvious clinical implications, and the irritative symptoms improved. Regarding the sexual domain, the scores worsened, and also increased over the first 6 months. The results of the confirmatory factor analysis were robust, with an explained variance of 0.951 and covariance of 0.929.
The Portuguese version of the EPIC-CP is a reliable and valid questionnaire for postoperative patients, and very useful to improve the knowledge of the early functional outcomes of men treated for prostate cancer.
《临床实践扩展前列腺指数综合量表（EPIC-CP）》是 EPIC 的一个简短版本，旨在促进该工具在常规护理中的使用。本研究旨在验证 EPIC-CP 的葡萄牙语版本，并评估其在展示拉丁美洲转诊中心接受手术治疗的前列腺癌患者早期功能结果方面的作用。
2017 年 3 月至 2018 年 6 月，在单一机构中，所有局限性前列腺癌患者在接受机器人辅助根治性前列腺切除术前、后，均前瞻性地、单独地自我管理 EPIC-CP。为了进行验证，我们使用 Cronbach's alpha 系数评估内部一致性。比较了手术前和手术后 6 个月和 12 个月的 EPIC-CP 各域值。使用学生 t 检验、Wilcoxon 和 Friedman 检验进行统计学分析，p 值 < 0.05 被认为有统计学意义。
共有 152 名患者回答了 EPIC-CP。患者的中位年龄为 62.7（±8.5）岁，前列腺特异性抗原水平为 6.3（±4.6）ng/ml。除“活力/激素”域外，所有域的 Cronbach's alpha 均在 0.75 至 0.77 之间，具有良好的内部一致性，而“活力/激素”域的得分为 0.35。术前和术后 6 个月组的域演变表明，与尿控和肠道相关的域恶化，并在最初的 6 个月内增加；然而，这种变化没有明显的临床意义，刺激性症状有所改善。关于性域，评分恶化，并且在前 6 个月内也增加。验证性因子分析的结果是稳健的，解释方差为 0.951，协方差为 0.929。
EPIC-CP 的葡萄牙语版本是一种可靠且有效的术后患者问卷，非常有助于提高治疗前列腺癌患者早期功能结果的认识。
